US Dermatology OTC Medications Market to Grow at a CAGR of 2.1% to reach US$ 1,124.56 million from 2020 to 2028

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. US Dermatology OTC Medications Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. US Dermatology OTC Medications Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Increasing prevalence of skin disorders
5.1.3 Rising demand for self-medication
5.1.4 Growing awareness about skin health
5.1.5 Expanding product portfolio by key players
5.1.6 Availability of a wide range of OTC products
5.1.7 Rising consumer preference for non-prescription treatments
5.1.8 Growth of e-commerce platforms for product distribution
5.1.9 Advancements in dermatological formulations
5.1.10 Aging population driving demand for skincare
5.1.11 Increased focus on natural and organic ingredients
5.1.12 Expanding dermatology awareness in emerging markets
5.1.13 Influence of social media and beauty trends on skincare choices

5.2 Market Opportunities

5.2.1
5.2.2 Expansion into emerging markets
5.2.3 Development of natural and organic product lines
5.2.4 Growing demand for anti-aging skincare solutions
5.2.5 Opportunities in digital platforms and telemedicine for product promotion
5.2.6 Increasing focus on personalized skincare
5.2.7 Rising consumer interest in preventive skincare
5.2.8 Partnerships with dermatologists for product endorsement
5.2.9 Innovation in combination therapies
5.2.10 Rising demand for pediatric dermatology products
5.2.11 Strategic acquisitions and collaborations among key players
5.2.12 Growing opportunities for OTC treatments for chronic skin conditions
5.2.13 Expansion of e-commerce sales channels

5.3 Future Trends

5.3.1
5.3.2 Increased focus on AI-driven skincare solutions
5.3.3 Growth in multifunctional skincare products
5.3.4 Rise of personalized skincare based on genetic testing
5.3.5 Integration of sustainable and eco-friendly packaging
5.3.6 Proliferation of microbiome-based skincare products
5.3.7 Expansion of digital dermatology consultations
5.3.8 Advancements in teledermatology and remote prescriptions
5.3.9 Enhanced product formulations with biotechnology
5.3.10 Shift toward more preventive and holistic skincare approaches
5.3.11 Increased regulation and standardization of OTC dermatology products
5.3.12 Rising demand for dermatologically tested and clinically proven products
5.3.13 Adoption of wearable devices for skin health monitoring

5.4 Impact of Drivers and Restraints

6. US Dermatology OTC Medications Market Regional Analysis

6.1 US Dermatology OTC Medications Market Overview

6.2 US Dermatology OTC Medications Market Revenue 2018-2028 (US$ Million)

6.3 US Dermatology OTC Medications Market Forecast Analysis

7. US Dermatology OTC Medications Market Analysis – by Product Type

7.1 Tablets and Capsules

7.1.1 Overview
7.1.2 Tablets and Capsules: US Dermatology OTC Medications Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Oils

7.2.1 Overview
7.2.2 Oils: US Dermatology OTC Medications Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Gels

7.3.1 Overview
7.3.2 Gels: US Dermatology OTC Medications Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Creams and Ointments

7.4.1 Overview
7.4.2 Creams and Ointments: US Dermatology OTC Medications Market – Revenue and Forecast to 2031 (US$ Million)

8. US Dermatology OTC Medications Market Analysis – by Indication

8.1 Dermatitis

8.1.1 Overview
8.1.2 Dermatitis: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

8.2 Acne

8.2.1 Overview
8.2.2 Acne: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

8.3 Psoriasis

8.3.1 Overview
8.3.2 Psoriasis: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Skin Bleaching

8.4.1 Overview
8.4.2 Skin Bleaching: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Anti-Fungal

8.5.1 Overview
8.5.2 Anti-Fungal: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Wart Remover

8.6.1 Overview
8.6.2 Wart Remover: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

9. US Dermatology OTC Medications Market Analysis – by Route of Administration

9.1 Topical

9.1.1 Overview
9.1.2 Wart Remover: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

9.2 Oral

9.2.1 Overview
9.2.2 Wart Remover: US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

10. US Dermatology OTC Medications Market – United States Analysis

10.1 United States

10.1.1 US Dermatology OTC Medications Market Breakdown, by Key Country, 2021 and 2028 (%)
10.1.1.1 US Dermatology OTC Medications Market – Revenue and Forecast Analysis – by Country
10.1.1.1 United States : US Dermatology OTC Medications Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.1.1 United States : US Dermatology OTC Medications Market Breakdown, by Product Type
10.1.1.1.2 United States : US Dermatology OTC Medications Market Breakdown, by Indication
10.1.1.1.3 United States : US Dermatology OTC Medications Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. US Dermatology OTC Medications Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Bausch Health Companies Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Perrigo Company Plc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bayer AG

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Viatris Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Johnson and Johnson Services, Inc.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 LEO Pharma A/S

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 GlaxoSmithKline Plc.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Galderma

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Dr. Reddy's Laboratories

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Acella Pharmaceuticals, LLC

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights